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Abstract
In a longitudinal cohort of ,700 children in New York City, the prevalence of asthma (.25%) is among the highest in the
US. This high risk may in part be caused by transplacental exposure to traffic-related polycyclic aromatic hydrocarbons
(PAHs) but biomarkers informative of PAH-asthma relationships is lacking. We here hypothesized that epigenetic marks
associated with transplacental PAH exposure and/or childhood asthma risk could be identified in fetal tissues. Mothers
completed personal prenatal air monitoring for PAH exposure determination. Methylation sensitive restriction
fingerprinting was used to analyze umbilical cord white blood cell (UCWBC) DNA of 20 cohort children. Over 30 DNA
sequences were identified whose methylation status was dependent on the level of maternal PAH exposure. Six sequences
were found to be homologous to known genes having one or more 59-CpG island(s) (59-CGI). Of these, acyl-CoA synthetase
long-chain family member 3 (ACSL3) exhibited the highest concordance between the extent of methylation of its 59-CGI in
UCWBCs and the level of gene expression in matched fetal placental tissues in the initial 20 cohort children. ACSL3 was
therefore chosen for further investigation in a larger sample of 56 cohort children. Methylation of the ACSL3 59-CGI was
found to be significantly associated with maternal airborne PAH exposure exceeding 2.41 ng/m
3 (OR=13.8; p,0.001;
sensitivity=75%; specificity=82%) and with a parental report of asthma symptoms in children prior to age 5 (OR=3.9;
p,0.05). Thus, if validated, methylated ACSL3 59CGI in UCWBC DNA may be a surrogate endpoint for transplacental PAH
exposure and/or a potential biomarker for environmentally-related asthma. This exploratory report provides a new blueprint
for the discovery of epigenetic biomarkers relevant to other exposure assessments and/or investigations of exposure-
disease relationships in birth cohorts. The results support the emerging theory of early origins of later life disease
development.
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Introduction
Asthma is the most common chronic childhood disease [1] and
its risk may be strongly influenced by prenatal events [2]. Low
income communities experience some of the highest childhood
asthma rates in the U.S [3] and new preventive strategies are
lacking due in part to the absence of predictive biomarkers. In our
longitudinal cohort study of children residing in urban low-
income, minority communities of New York City [4–6] the asthma
rate exceeds 25% and is among the highest in the nation.
Preliminary evidence suggests that transplacental exposure to
polycyclic aromatic hydrocarbons (PAHs) derived largely from
traffic-related air pollutants may be a risk factor for the early
development of asthma-related symptoms in this cohort [5].
However, we could not rule out the possibility that postnatal
exposure of children in this cohort to these pollutants may also
contribute to the symptoms without additional studies.
According to the hypothesis of the early origins of chronic
disease, exposure to agents that are transmissible from mother to
fetus has profound influences on the functional capacity and
performance of many organs/tissues later in life [7–11].
Developmental plasticity allows the fetus to make anticipatory
responses to the external environment by altering the course of
cellular and organ differentiation in utero in order to gain adaptive
advantages for later life challenges. However, a pronounced
mismatch between ‘‘anticipatory adaptations’’ made during early
life and demands in later life could be a cause of disease [10].
More importantly, environmental insults could ‘‘mislead’’ early
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studied mechanisms underpinning the latter scenario is the
induction of aberrant DNA methylation of regulatory sequences
in susceptible genes by environmental toxicants during critical
developmental periods, leading to inappropriate gene expression
and disease pathogenesis in later life [12–16]. This body of
research suggests that transplacental exposure to high levels of
airborne PAHs could cause aberrant DNA methylation changes,
leading to dysregulation of gene expression and perhaps childhood
asthma. These alterations could occur, not only in target organs/
tissues such as fetal lung or the immune system [11], but also in
peripheral tissues such as fetal circulating white blood cells and
placental tissues, thus providing opportunities to discover and
develop highly sensitive and specific, minimally invasive biomark-
ers for exposure assessments or clinical indications [17].
The primary objective of this study was to explore whether
transplacental exposure to PAHs in humans induces epigenetic
reprogramming involving aberrant DNA methylation of specific
genes that might be mechanistically related to childhood asthma
or airway inflammation. Study subjects were children born to
nonsmoking Dominican and African American women living in
Northern Manhattan and the South Bronx. They were partici-
pants in the Columbia Center for Children’s Environmental
Health (CCCEH) cohort study previously described [4–6].
Mothers completed prenatal air monitoring and donated a
maternal and/or umbilical cord blood sample and, in some cases,
fetal placental tissue (FPT) at delivery. Umbilical cord white blood
cells (UCWBC) and matched FPT from 20 cohort subjects were
used initially for candidate identification and selection, as it is not
feasible to obtain lung/immune cells in newborns. UCWBC
provide a reasonable surrogate for our target organ/tissue (lung/
immune cells) because they contain stem cells that can populate
the lungs in later life and also provide a rich source of T cells [18]
which are important producers of cytokines and other asthma
mediators. The matched FPT provides ample tissue for obtaining
fetal RNA to verify correlative changes in gene expression. A
larger sample of 56 cohort subjects was used to validate the
markers identified. Methylation of a 59-CpG island (CGI) in acyl-
CoA synthetase long-chain family member 3 (ACSL3) was found to be
positively and significantly associated with the level of maternal
PAH exposure and with a parental report of asthma symptoms
prior to age 5 in this exploratory study.
Results
Identification of candidate genes and selecting the most
relevant candidate
Figure 1 shows the work flow used in the discovery of candidates
and strategies employed for selecting candidate genes associated
with prenatal airborne PAH exposure and with asthma.
Twenty participants were randomly selected without knowledge
of asthma classification: ten with maternal PAH exposure levels
below the CCCEH cohort median of 2.3 ng/m
3 (‘‘low PAH
group’’) and ten with prenatal PAH levels above the cohort median
(‘‘high PAH group’’). Methylation-sensitive restriction fingerprint-
ing [19,20] was performed to identify candidate sequences
displaying differential methylation status between high and low
PAH groups. Both hypo- and hyper-methylated candidate sequenc-
es in the high PAH group when compared to the low PAH group
were selected. In silico analyses revealed that 19 out of 31 sequenced
candidates were homologous to known genes (Table 1) and 6 of
these aligned to a CGI(s) located in the 59 flanking region (proximal
promoter and/or exon/intron 1) of a known gene (59-CGI)
(Figure 2). These 6 genes therefore were chosen as candidates for
further investigation. Unexpectedly, all six candidates were found
be hypermethylated sequences in the high PAH group when
compared to the low PAH group. A literature search showed that
they are expressed in the lung and/or lymphoid tissues and have
functions related to inflammatory/or other immune responses (dual
specificity phosphatase 22; DUSP22, accession # BC022847, [21]),
DNA damage and repair (RAD21 homolog (S. pombe); RAD21,
accession # BC050381, [22]), fatty acid metabolism (ACSL3,
accession # BC041692, [23]; stearoyl-CoA desaturase 5; SCD5,
accession # NM_001037582, [24] ), gene transcription (Scm-like
with four mbt domains 2; SFMBT2, accession# NM_001029880, [25];
WW domain containing oxidoreductase; WWOX, accession # AF211943,
[26] ). Bisulfite sequencing analyses of the initial 20 UCWBC
samples confirmed a good agreement between hypermethylation of
all of the candidates’ 59-CGI(s) and either high or low PAH
exposure status, consistent with MSRF findings (Table 1).
We next determined the strength of the relationship between the
percent of methylation of a candidate gene’s 59-CGI in UCWBC
DNA samples and its transcript expression level in matched FPT
RNA samples (Table 2 and 3). The degree ofmethylation ofa region
encompassing the entire predicted 59-CGI for each candidate gene
was determined by bisulfite sequencing (Figure 2, the location of the
amplicon was marked as BSPCR) and mRNA levels determined by
real time RT-PCR. The percentage of promoter methylation
(Met%) determined by bisulfite sequencing and relative gene
expression levels (RER) determined by real time RT-PCR of all
six candidates tested on 14 paired UCWBC DNA and FPT RNA
samples are presented in Table 2. The degree of concordance
between these two parameters for each candidate is shown in
Table 3. We found that the degree of ACSL3 59-CGI methylation
and the level ACSL3 transcript expression exhibited the expected
inverse relationship with the highest concordance and significance
(t=20.45; p,0 . 0 1 )w h e nc o m p a r e dt ot h eo t h e rc a n d i d a t e s .T h e s e
findings indicate that the ACSL3 59-CGI is likely a regulatory CGI
since increased cytosine methylation in this sequence in UCWBC
DNA samples was found to be significantly associated with
transcriptional silencing of the gene in matched FPTs.
To further demonstrate that the methylation status of the ACSL3
promoter affects gene expression, we used a lung non-small
carcinoma cell line H1299 as a model system. Two series of
experiments were performed. In the first series, we treated H1299
cells with a DNA demethylation agent, 5-aza-29-deoxycytidine (5-
aza-dC), and found that ACSL3 expression was significantly
increased (Figure 3A) along with promoter demethylation (data
not shown). These data provide evidence that demethylation of the
ACSL3 promoter is associated with enhancement of gene
expression. In the second series of experiments, H1299 cells
exposed to low doses of benzo[a]pyrene (BaP; 0.01 to 1 nM), a
representative PAH, showed a dose-dependent decrease in ACSL3
transcript expression as indicated by real time RT-PCR analysis
(Figure 3B) and increased promoter hypermethylation as revealed
by bisulfite sequencing (Figure 3C). These data strongly support
the notion that the CpG island in the ACSL3 promoter plays a
regulatory role in gene expression.
Association of methylation status of ACSL3 59CGI with
PAH exposure in the larger sample
ACSL3 was chosen for subsequent assessment of the relation-
ships between prenatal PAH exposure and gene 59-CGI
methylation status and for exploratory analyses of PAH exposure
status and asthma classification in a larger sample of 56 children
from the CCCEH cohort.
The organization of the 59-flanking sequence in the promoter
region of ACSL3is shown inFigure4A.Beforewe conductedthe full
PAH, Epigenetic and Asthma
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quality control experiments were performed. First, bisulfite
sequencing analyses of an amplicon encompassing the entire
predicted ACSL3 59-CGI (Figure 4A, BSPCR marks the amplicon)
were performed on the 20 UWBC DNA samples; five from each of
the high or low PAH groups with or without asthma. Bisulfite
sequencing data (Figure 4B) showed that hypermethylation of this
CGI was found to be strongly associated with maternal exposure to
a PAH level higher than the cohort median of 2.3 ng/m
3. Asthma
status did not seem to affect methylation status of ACSL3 promoter.
Second, based on bisulfite sequencing data, we designed and
optimized three methylation-sensitive-PCR (MSPCR) protocols
[27,28] to amplify three regions (R1, R2 and R3) within the CGI
that exhibited the greatest differential methylation changes between
samples from the ‘‘high PAH’’ and the ‘‘low PAH’’ groups
regardless of asthma status (Figure 4A, R1–3 are marked). These
three regions were closely flanking the transcriptional start site
(TSS). We further validated that the methylation status of R1
exhibited the strongest correlation with bisulfite sequencing data
from analyses of the entire CGI. Representative data from MSPCR
Figure 1. The workflow chart outlines how to discover the methylated genes in a step-by-step manner. Initially, ten umbilical cord white
blood cell (UCWBC) samples from children with maternal (prenatal) PAH exposure above and ten with prenatal exposure below the cohort median
were selected irrespective of gender and ethnicity. DNA was isolated from the sample was dichotomized according to the median of prenatal PAH
exposure obtained from 48-hour personal air monitoring of the mothers during pregnancy (the cohort median is 2.3 ng/m3). Candidates with
differentially methylation status between the samples from the two groups were discovered by Methylation Sensitive Restriction Fingerprinting
(MSRF) following by subcloning and sequencing. Candidates were further identified by in silico analysis from databases from NCBI and UCSF genomic
centre. Candidates which contained CpG island (CGI; CG rich region with .60% GC content and obs/exp ratio .0.6) on its 59 flanking region were
chosen for bisulfite sequencing to confirm the dependency of the methylation status of the CGI in a candidate gene on maternal PAH exposure. Six
genes confirmed to have the latter relation were subjected to gene expression analysis in the 14 matched fetal placental tissues (FPT). The ACSL3 was
found to have the highest concordance between degree of CGI methylation and level of gene expression in reverse manner. It was therefore selected
for the final analyses for correlation between methylation status of its CGI and transplacental PAH exposure and/or parent reported asthma
symptoms of childhood asthma up to age 5 in a case-control study comprised of 56 participants. For this part of the study, Methylation specific-PCR
(MSPCR) protocol was optimized to analyze the methylation status of R1 in Figure 4A was used as the high throughput method to analyze this larger
sample set.
doi:10.1371/journal.pone.0004488.g001
PAH, Epigenetic and Asthma
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above (high PAH) or below (low PAH) the cohort median are
illustrated in Figure 4C. Thus, MSPCR of R1 was chosen as the
high throughput method for investigating the methylation status of
the ACSL3 59-CGI in the larger sample comprised of 56 children.
Receiver Operating Curve (ROC) analysis of data from 56
subjects identified the maternal PAH exposure cutpoint value that
best distinguished methylated versus unmethylated ACSL3 59CGI
status determined by MSPCR to be 2.41 ng/m
3 (Figure 5). The
Area Under ROC curve (AUC) value was 0.82 suggesting excellent
separability of the subjects with methylated or unmethylated ACSL3
59CGI. Using the ‘‘optimal’’ cutpoint value, methylation status was
predicted with 75% sensitivity, 82% specificity.
Table 4 shows that 30 of the 56 children had a methylated
ACSL3 59-CGI; 81% of these 30 children were born to mothers
with PAH exposure equal or exceeding 2.41 ng/m
3, the cutpoint
value determined by the ROC analysis. Thus, methylation was
positively and significantly associated with maternal PAH
Table 1. Differentially methylated candidate genes with 59CpG Islands identified with MSRF.
Clone Pr1 Pr2
Hyper-
methylation Chr Band Gene homology Location
CGI at
59 end Gene Ontology
A1 20 21 Low PAH 8q24.3 NIK and IKKbetta-binding protein INTRON15 NF-kappaB-inducing
kinase acitivity
A2 20 21 High PAH 6p25.1 cDNA clone IMAGE:4825327 59 END
A3 20 21 High PAH 1q41 N/A
A4 20 21 High PAH 19p13.3 cDNA clone FLJ14311 INTRON2
A5 20 21 High PAH 10q26.3 N/A
A6 20 21 High PAH 11q12.1 N/A
A7 20 21 High PAH 8q24.11 Protein in DNA double-strand break
repair, RAD21
59 END ,1 kb Double strand
break repair
A8 20 21 High PAH 6p25.3 Dual specificity phosphatase 22,
DUSP22
INTRON1 ,1 kb Stress kinase involved
in MAPK pathway
A9 20 21 High PAH 8p23.1 Beta-defensin 107, DEFB107 39 END Defense response
B1 22 23 High PAH 1q32.2 mRNA for KIAA0463 protein, partial cds INTRON4
B2 22 23 High PAH 2p24.2 N/A
B3 22 23 High PAH 3q24 WIAF-4002-STS Human THudson EST
STS cDNA
INTRON1
B4 22 23 High PAH 1q41 N/A
D1 22 23 Low PAH 2p24.2 N/A
D2 22 23 Low PAH 1q32.1 N/A
D4 22 23 Low PAH 15q22.2 Vacuolar protein sorting-associated
protein 13C, VPS13C
EXON7 Trans-Golgi to endosome
transport
D5 22 23 Low PAH 1q41 N/A
D6 22 23 High PAH 19p13.2 N/A
D7 22 23 High PAH 2q36.1 Acyl-CoA synthetase long-chain
family member 3, ACSL3
INTRON1 ,1 kb Fatty acid metabolism
D8 22 23 Low PAH 11q25 cDNA clone DKFZp686H1949 INTRON1
D9 22 23 Low PAH 1p32.3 Clone BNGH42007037, similar to zinc
finger protein GLI1
INTRON1
D10 22 23 Low PAH 14q21.1 CTAGE-5B protein mRNA, complete
cds, alternatively spliced
INTRON1
E1 7 11 High PAH 4q21.22 Stearoyl-CoA desaturase 5, SCD5 INTRON1 ,1 kb Fatty acid metabolism
E2 7 11 High PAH 16p13.11 N/A
E3 7 11 High PAH 16q24.2 Junctophilin 3, JPH3 INTRON3 Integral to membrane
E4 7 11 High PAH Xq13.1 Ribosomal protein S4, X-linked INTRON8 Translation
F1 10 11 High PAH 11q23.1 N/A
F3 10 11 High PAH 10p14 Scm-like with four mbt domains 2,
SFMBT2
INTRON1 ,2 kb Gene transcription
F4 10 11 High PAH 16q13 Small inducible cytokine A17 precursor,
CCL17
INTRON2 Chemokine activity
G1 22 11 Low PAH 13q32.3 N/A
G2 22 11 Low PAH 16q23.1 WW domain-containing
oxidoreductase isoform , WWOX
INTRON1 ,1 kb Gene transcription
Note: Sequences were identified based on BLAT (UCSC genome center database) and RefSeq (NCBI database) search.
Abbreviation: NA, not available.
doi:10.1371/journal.pone.0004488.t001
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WWOX. The CGI(s) (shaded in blue in the genomic DNA sequence) were identified in silico based on a CG content .60%, with an observed/expected
ratio of 0.6 according to instructions from MethPrimer. TSS: Transcription start site. The nested PCR-amplified region was indicated by a line with
double arrow heads and methylation status of this region was determined by bisulfite genomic sequencing.
doi:10.1371/journal.pone.0004488.g002
Table 2. Percentage of promoter methylation (Met%) in UCWBC DNA samples and relative expression ratio (RER) in FPT RNA
samples of all six candiate genes*.
Sample ACSL3 RAD 21 DUSP22 SCD5 SFMBT2 WWOX
Low PAH
PAH
level
Overall
Met% RER
Overall
Met% RER
Overall
Met% RER
Overall
Met% RER
Overall
Met% RER
Overall
Met% RER
#813 1.71 42 0.25 46 2.22 52 26.72 25 0.46 44 204.08 85 0.87
#826 1.80 45 0.48 56 0.58 42 9.31 33 0.71 36 3.06 85 0.74
#926 1.50 48 3.07 35 6.36 35 6984.8 33 1.17 68 1438.5 86 0.25
#954 1.15 35 0.26 36 0.66 36 12.70 33 0.00 55 79.09 78 0.04
#1066 1.22 67 0.43 45 0.79 36 2.85 60 57.70 36 9308.0 78 0.01
#1090 1.47 45 1.88 40 0.56 36 148.16 48 0.09 36 62.25 75 3.95
#755 0.85 45 0.03 35 1.19 44 13.45 33 1.41 44 173.87 85 0.13
High PAH PAH
level
Overall
Met%
RER Overall
Met%
RER Overall
Met%
RER Overall
Met%
RER Overall
Met%
RER Overall
Met%
RER
#784 34.48 85 0.15 80 1.33 80 30.25 68 1.41 78 51.68 33 0.48
#831 2.41 81 0.34 90 2.18 85 5.15 68 0.95 68 0.29 51 0.16
#876 2.65 94 0.13 85 759.55 85 192.40 86 2.48 68 342.03 35 0.13
#901 2.82 95 0.14 85 0.80 85 10.72 85 0.19 75 15.07 35 0.97
#946 2.84 95 0.04 90 0.54 84 4.23 82 0.05 85 160.54 40 0.03
#1079 3.66 88 0.22 78 2.28 90 12.95 82 0.94 85 25.11 40 0.62
#1107 2.76 93 0.16 78 0.34 78 2.47 75 0.17 78 99.13 42 0.27
Note:
*Overall Met% is the percentage of methylated cytosine in the CGI(s) (regions mark as BSPCR in Fig 2) was determined by bisulfite sequencing; levels of gene
expression normalized to b-actin level as a ratio using values of transcripts in FPT samples matched to UCWBC samples (n=14) determined by real time RT-PCR.
doi:10.1371/journal.pone.0004488.t002
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59CGI in UCWBC DNA was 13.8, 95% CI=[3.8, 50.2]
(p,0.001), given the maternal PAH exposure was $2.41 ng/m
3,
compared to those exposed to ,2.41 ng/m
3. ACSL3 59CGI
methylation status was not affected by gender or ethnicity.
Relationship between ACSL3 59 CGI methylation and
asthma classification
Table 5 shows the percentage of subjects with methylated or
unmethylated ACSL3 59 CGI according to asthma classification.
Methylation of the ACSL3 59CGI was positively and significantly
associated with asthma classification. The odds ratio (OR) relating
methylation status and asthma classification among all 56 subjects
was 3.9, 95% CI=[1.1, 14.3] (p=0.03). Eleven of 15 children
classified as asthmatic (73%) had UCWBC DNA with a
methylated ACSL3 59-CGI. Table 5 further shows that the median
(minimum, maximum) values of maternal PAH exposure differed
significantly by methylation status of the ACSL3 59-CGI:
methylation=3.39 ng/m
3 (1.11, 34.5) and unmethyla-
tion=1.70 ng/m
3 (0.49, 3.33), respectively (p,0.001). All mater-
nal PAH exposure values except the maximum (34.5 ng/m
3) were
below 7.7 ng/m
3. When the latter analysis was repeated excluding
the extreme high PAH value, the p-value was unchanged.
Discussion
In this exploratory study, we have identified ACSL3 as a
candidate biomarker/gene whose 59-CGI methylation status
appears to be related to transplacental PAH exposure and further
associated with PAH-associated asthma. Thus, ACSL3 may be the
first potential surrogate endpoint for environmentally related
childhood asthma. If confirmed, such a biomarker holds promise
in assessing PAH exposure and as a clinically relevant predictor for
asthma risk in children born to mothers exposed to air pollutants
such as traffic-related combustion emissions.
We used a set of stringent criteria for the identification, selection
and validation of candidates, which resulted in choosing ACSL3
the final candidate for the 56-sample study. We first used an
unbiased method, MSRF, to identify both hypo- and hyper-
methylated sequences in the high PAH group compared to the low
PAH group. In silico analyses then revealed that 19 out of 31
sequences identified were homologous to known genes and 6 of
these aligned to a CGI(s) located in the 59 flanking region of a
known gene (59-CGI). These 6 genes therefore were chosen as
putative candidates for further investigation. By comparing the
degree of methylation of their 59CGI in UCWBC DNA samples
and levels of gene expression in FPT RNA samples we identified
ACSL3 to have the highest inverse concordance in vivo. We then
employed a lung cancer cell line (H1299) to demonstrate that the
demethylation of ACSL3 59-CGI by 5-aza-dC treatment induced
enhancement of gene expression in H1299. Conversely, the
treatment of H1299 with low doses of BaP, a PAH, was associated
with dose-dependent hypermethylaiton of ACSL3 5-CGI and gene
silencing. Collectively, these data strongly support methylation of
the 59-CGI of ACSL3 in gene regulation. They also provide
evidence that PAH could directly induce ACSL3 promoter
methylation. This well though out, step-wise approach allowed
us to identify a candidate to be tested in the 56-sample study to
determine whether methylation of the ACSL3 59CGI could be a
stand alone biomarker for PAH exposure and/or PAH-associated
childhood asthma.
Measuring human exposure to chemicals such as PAHs and
determining their relationship to disease outcomes is a challenge
for environmental health, especially when children are the study
subjects. Although some studies have found a positive correlation
between PAH-induced DNA adducts and mutagenesis or cancer
development [29] others have failed to establish clear cause-effect
relations between PAH adducts and the induction of these or other
disease outcomes [30], suggesting that other mechanisms may be
involved. Moreover, some of the methods for measuring genotoxic
mechanisms such as adducts are complex and low-throughput.
Therefore, it is of significance that, in this investigative study, we
have developed a relatively simple, high throughput assay based
on methylation of a sequence in the promoter of the ACSL3 gene
that appears to distinguish children born to mothers with high
airborne PAH exposure from those who were not (OR=13.8;
p,0.001) with high sensitivity (75%) and specificity (85%). The
Area Under ROC curve (AUC) value for this assay was 0.82
suggesting excellent separability of the subjects with the methyl-
ated or unmethylated ACSL3sequence. This optimized MSPCR
protocol allows for a rapid determination of ACSL3 59-CGI
methylation status in large sample sets, which is a normal
requirement in population studies. It also has the added advantage
to be developed into a minimally invasive test since only a small
amount of DNA from UCWBC is required for the assay. If
validated, such an assay is expected to have a high utility in the
assessment of PAH exposure in future population-based studies.
Multiple epidemiological studies have suggested that asthma risk
is determined by prenatal and/or early life exposure to pollutants
and allergens that modify later life lung function and T helper cell
allergic phenotype [11]. Epigenetic modifications of regulatory
genes crucial to the development of asthma-related pathophysiol-
ogy have been put forth as a possible mechanistic basis of this
disease [11]. Thus, asthma may be caused by epigenetic changes
such as DNA methylation, post-translational modifications of
histones, dysregulation of non-coding RNAs, and chromatin
alterations. At present, the best studied mechanism is DNA
methylation-mediated disruption of gene regulation. In this
regard, experimental data indicating that DNA methylation of
genes critical to the differentiation of T helper cells could skew
their response towards or away from an allergic phenotype lend
support to this theory [31–34]. Additionally, we recently
demonstrated that inhaled diesel exposure (a source of PAHs)
and intranasal Aspergillus fumigatus induced specific DNA methyl-
ation changes in the promoters of interferon-c and interleukin-4 in T
helper cells, respectively, and altered circulating levels of IgE in
Table 3. Concordance of degree of methylation of 59CGI(s) in
UCWBC samples and gene expression levels in FPT samples.
Gene Name tau* Confidence Interval p-value
ACSL3 20.45 [20.76, 20.15] ,0.01
RAD21 20.30 [20.70, +0.09] 0.13
DUSP22 20.31 [20.66, +0.05] 0.09
SCD5 20.11 [20.49, +0.26] 0.55
SFMBT2 20.23 [20.57, +0.10] 0.18
WWOX +0.22 [20.11, +0.55] 0.20
Note: % of methylated cytosine in the CGI(s) (regions mark as BSPCR in Fig 2)
was determined by bisulfite sequencing; levels of gene expression was
measured as steady state transcript levels in FPT samples matched to UCWBC
samples (n=14) quantified by real time RT-PCR.
*The Kendall tau coefficient was calculated between % of methylation and gene
expression; negative sign indicates inverse relationship. The larger the negative
value means greater negative correlation and statistical significance was
determined by a 2-tailed test with p,0.05.
doi:10.1371/journal.pone.0004488.t003
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fundamental questions related to asthma risk among human
populations remain; these can only be addressed by cohort studies
using specimens linked to well-annotated clinical and environ-
mental exposure data. Such cohort-driven epigenetic research has
the potential to address key questions, such as those concerning the
influence of early life factors, environmental exposure, other
disease states, and lifestyle factors on susceptibility to asthma. In
this proof-of-principle study, we developed an innovative ap-
proach to population-based studies of environmental epigenetics,
which could easily be implemented in future large-scale investi-
gations.
A range of approaches is available to obtain quantitative and
qualitative information on genomic DNA methylation changes
[27]. We chose methylation sensitive restriction fingerprinting (
MSRF; [19,20] ) as a tool for the discovery of PAH-reprogram-
mable genes in UCWBC due to its high sensitivity, requirement
for very small amounts of starting materials (,100 ng), and the
ease in visual identification of differentially methylated sequences
among a moderately large number of samples. Using only four
arbitrary primers and six permutations of MSRF analyses on
UCWBC samples from the high and low PAH exposure groups,
we discovered 31 differentially methylated sequences. In future
studies more arbitrary primers could be used to cover a larger
portion of the genome in order to uncover more candidates [27].
In this study we had overcome another technical hurdle related to
the quantification of gene expression in UCWBC. This task is
challenging because the amount of cellular components in
umbilical cord blood is usually very limited and prohibitive for
high quality RNA isolation. To circumvent this problem, in a
subset of samples, we assessed the concordance between the
extents of methylation in the promoter-CGI(s) of each gene (using
UCWBC DNA samples) with its respective transcript expression
levels in RNA samples isolated from matched FPT samples. This
choice was based on the logic that both UCWBC and FPT are
fetal tissues are subjected to similar environmental exposure
through the mother. Our results demonstrated good concordance
for at least the ACSL3 gene. In future design of such an epigenetic
epidemiology experiment, preference should be given to improved
techniques for the isolation of RNA and DNA from the UCWBC.
ACSL3 belongs to the acyl-CoA synthetase long chain (ACSL)
family of genes which encodes key enzymes in fatty acid
metabolism [36]. ACSL3 is expressed in lung and thymic tissue
[37,38]. Intracellular conversion of long chain fatty acids to acyl-
CoA is required for energy production. ACSL catalyzes the initial
step in this conversion yielding acyl-CoAs, which are used both in
the synthesis of cellular lipids and in degradation via beta-
oxidation for energy production [39,40]. Moreover, acyl-CoA
synthetase can catalyze the ATP-dependent production of
arachidonoyl-CoA that is a substrate for lysophosphatidyl
acyltransferase involved in arachidonic acid-containing phospho-
lipid remodeling in proliferating T cells [41]. Lipid metabolism
influences membrane proteins, including ion channels. In the lung,
ACSL3 is found most abundantly in microsomal and cell
membrane fractions, with mitochondria as the next richest source
[42]. Inhibition of ACS enzyme activity has been shown to cause
cell death in p53-defective lung cancer cells [43]. Thus
hypermethylation of this gene in T helper cells or lung tissues is
expected to diminish fatty acid utilization and beta-oxidation-
energy production, and possibly influence membrane phospholip-
id composition. Whether these functional changes directly affect
asthma is unknown. However, several epidemiological studies
show that fatty acid composition in milk [44,45], diet [46,47], and
umbilical cord blood [48] affects the development of allergy and
other inflammatory diseases including asthma. For example,
dietary omega-3 (n-3) fatty acids having a variety of anti-
inflammatory and immune-modulating effects may affect allergy
and asthma. Further mechanistic studies in in vitro and in vivo
experimental models are needed to decipher the role of ACSL3 in
childhood asthma. Interestingly, ACSL3 is located in 2q36.1 which
has recently been shown to be associated with regions of the
asthma susceptibility loci, in specific populations [49–50]
Finally, the current finding of a putative epigenetic marker that
is associated with PAH exposure and asthma adds to other
evidence from the CCCEH cohort that PAHs increase risk of
respiratory symptoms and probable asthma. At age 2 years,
significantly more difficulty breathing and more probable asthma
were reported among children jointly exposed prenatally to PAHs
and postnatally to environmental tobacco smoke (ETS) (OR for
probable asthma=7.52, 95% CI 1.71–33.11, p,0.01) [3]. These
relationships were reexamined through age 5 years and similar
trends were detected, with an observed interaction between high
prenatal PAH exposure and postnatal ETS on wheeze and
probable asthma at age 5 (OR=5.48, 95% CI 1.17–25.58,
p,0.01) (unpublished data). A parallel cohort study in Krakow,
Poland has found a significant relationship between prenatal PAH
exposure and respiratory symptoms [51]. In a subset of 333
subjects, PAH exposure measured during pregnancy by personal
air monitors was associated with an increased risk for wheezing
without cold (RR 3.8; 95% CI: 1.2–12.4), during the course of the
infant’s first year of life [51].
In conclusion, no previous studies have examined the effects of
prenatal exposure to ambient air pollutants on DNA methylation
patterns in genes potentially associated with the asthma phenotype
of the offspring. This is an important gap in our understanding of
asthma pathogenesis. Given the potential importance of epigenetic
mechanisms in the etiology of childhood asthma, research is
needed to identify an epigenetic profile related to PAH-associated
childhood asthma and determine whether reprogramming events
associated with transplacental exposure to PAHs increase risk of
childhood asthma. The current report of ACSL3 as a candidate
biomarker of PAH exposure and a putative predictor of PAH-
associated childhood asthma represents an important first step in
this area of research. Finally, the novel design of this study could
serve as a prototype approach for future discoveries of additional
exposure biomarkers or surrogate disease endpoints in other birth
cohort studies.
Materials and Methods
Study Population
Study subjects were nonsmoking Dominican and African
American women and their children residing in Washington
Heights, Central Harlem and the South Bronx participating in the
CCCEH cohort study previously described [4–6]. Written
informed consent was obtained from all subjects following
procedures approved by the Institutional Review Board of the
New-York Presbyterian Medical Center. Full enrollment into the
study required completion of prenatal air monitoring and
collection of a maternal and/or umbilical cord blood sample at
delivery. As of November 1, 2007, 74% of the more than 600 fully
enrolled subjects had been retained in the cohort through at least
five years. During pregnancy and following delivery, a trained
bilingual research team administered repeat questionnaires
eliciting environmental and respiratory health histories [4]. There
were no differences in demographics of subjects fully enrolled and
those lost to follow-up [4–6]. Based on parental report of a doctor’s
diagnosis of asthma or probable asthma before the age of five,
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or without a parental report of asthma’’).
Study Sample Selection
All subjects with stored UCWBC and paired FPT were eligible
for inclusion in this proof-of-principle study. The population was
dichotomized on the median PAH value of the entire cohort
(2.3 ng/m
3). Half of the 56 subjects in the present study were
selected from among the ones above this median (the high PAH
exposure group) and half from among those below the cohort
median (the lower PAH exposure group). Twenty subjects (10 high
and 10 low exposure) were used to identify UCWBC DNA
sequences whose methylation status was dependent on maternal
PAH exposure (high versus low) and to validate concordant
transcript changes in matched FPT samples. All 56 samples were
then used to validate the association between PAH exposure and
ACSL3 59CGI methylation and to explore the association between
ACSL3 59CGI methylation and childhood asthma status. Table 6
shows the characteristics of the cohort population and study
sample, respectively. The sample was representative of the cohort
population in terms of maternal age, child’s sex, median PAH
exposure, and percentage of children with probable asthma;
however, the sample differed with respect to ethnicity. Table 7
showed the PAH distribution and variation in PAH levels in
selected and unselected cohorts.
Monitoring and Sample Collection
Personal prenatal air monitoring was conducted for two
consecutive days on all participants during the 3
rd trimester of
pregnancy as previously described [4–6]. Levels of pyrene and
eight carcinogenic PAHs were analyzed (4). Total PAH levels for
each participating mother were computed as the sum of the eight
carcinogenic PAHs, where the values below the limit of detection
were imputed as 0.125 ng/m
3 (the median value between 0 and
the limit of detection). Umbilical cord blood (30–60 mL) was
collected at delivery. The buffy coat, packed red blood cells, and
plasma samples were separated and stored at 280uC. DNA
(100 ng–500 ng) was extracted from UCWBCs. For some
UCWBC samples, matched FPTs were also available and total
RNA was extracted using a TRIZOLH (Invitrogen, CA) according
to manufacturer’s protocol. All samples were coded.
Methylation Sensitive Restriction Fingerprinting (MSRF)
MSRF was performed in a single-blinded manner on asthma
classification, as previously described [19,20]. Five hundred ng of
UCWBC DNA was restriction-digested using MseI [New England
Biolabs, MA] alone or in combination with BstUI [New England
Biolabs, MA] and amplified by PCR with various combinations of
paired arbitrary primers (Table 8). Following electrophoresis,
candidate sequences displaying differential methylation status
between the ‘‘high PAH group’’ and ‘‘low PAH group’’ were
isolated, extracted from the gel, cloned, identified and aligned with
various databases. Sequences matched to known genes and with
59-CGIs were selected for bisulfite genomic sequencing and
confirmation studies of their regulatory function in gene
expression. Six candidates [ACSL3, RAD21, DUSP22, SFMBT2,
SCD5 and WWOX] were selected.
Treatment of H1299 with 5-aza-dC and BaP
H1299 cell line is a gift from Dr. Carolyn M. Klinge (University
of Louisville) and were maintained in RPMI-1640 medium
(Invitrogen, CA) supplemented with 10% fetal bovine serum
(Hyclone, UT), 10 mM HEPES (Invitrogen, CA), 1 mM sodium
pyruvate (Invitrogen, CA) and 4500 mg/L glucose (Invitrogen,
CA). For demethylation assays, cells were treated with 0.5 and
1.0 mM 5-aza-dC (Tocris, MO) with DMSO (Sigma, MO) as
control every 2 days for a total of 8 days. For BaP treatment, cells
were exposed to 0.01, 0.1 and 1.0 nM BaP (Sigma, MO) with
DMSO as control every 2 days for a total of 4 days. Medium was
replenished with new drug of 5-AZA-dC or BaP every 48 hr.
DMSO was added in the control samples. RNA was isolated,
reverse transcribed and undergone real-time PCR. DNA was
isolated, bisulfite-modified and undergone bisulfite genomic
sequencing.
Bisulfite genomic sequencing
Genomic DNA (100 ng) from UCWBC samples or H1299 cells
was modified with sodium bisulfite by using the EZ Methylation
Modification Kit (Zymo Research, CA) before conducting PCRs.
In silico analyses and detailed database searches were used to
predict the 59-CGI(s) in each gene. Primers were designed to
amplify ,0.9 to 1.4 kb fragments encompassing the 59-CGI(s) of a
candidate gene from bisulfite-modified DNA (Table 8). Amplicons
were generated from individual UCWBC sample and subcloned
into the pCR2.1 vector (Invitrogen, CA); eight or more clones
were picked and sequenced (Macrogen, Korea).
MSPCR analyses
Bisulfite-modified genomic DNA was subjected to MSPCR
analyses [27,28]. Three sets of primers were designed to amplify
regions (Figure 3A; R1, R2, and R3) within the 59-CGI that
exhibited the highest degree of differential methylation between
the high and low PAH group. For each region, the M primer set
amplifies the target sequence when it is methylated; the U primer
set only amplifies the unmethylated allele (Table 8). Thirty-five-
cycle PCRs were performed with 1 unit Platinum Taq DNA
polymerase (Invitrogen, CA) using the following conditions:
denature at 94uC for 30 s, anneal at 58uC for 1-min, and extend
at 72uC for 1-min, followed by 12-min final extension. PCR
products were separated on 2% agarose gel and visualized with
ethidium bromide.
Real-time reverse-transcriptase-PCR (real time RT-PCR)
Total RNA was isolated from FPT samples matched to
UCWBC samples or from H1299 cells as previously reported
[14,16]. Steady state mRNA levels of the genes under investigation
Figure 3. Real-time PCR analysis of gene expressions of ACSL3 in non-small cell lung cancer H1299 cell line in response to (A) 5-aza-
deoxycytidine (5AZA-dC) and (B) benzo[a]pyrene (BaP) and bisulfite genomic sequencing analysis of ACSL3 promoter methylation
status in response to BaP (C). A: Cells were treated with 0.5 and 1.0 mM 5-AZA-dC with DMSO as control every 2 days for a total of 8 days. B: Cells
were treated with 0.01, 0.1 and 1.0 nM BaP with DMSO as control every 2 days for a total of 4 days. RNA was isolated, reverse transcribed and
underwent real-time PCR. The 2-DDCt method was used to calculate the relative expression level of transcripts normalized to b-actin. *Statistically
significant differences between exposed and control was accepted at p,0.05. C: Diagram represents methylation status of ACSL3 promoter of H1299
cells exposed to BaP assayed by bisulfite genomic sequencing. Cells were treated with 0.01, 0.1 and 1.0 nM BaP with DMSO as control every 2 days for
a total of 4 days. Open circle: unmethylated CG; closed circle: methylated CG. Putative transcription factor binding sites such as Sp1, AP2, GCF, c-fos
and junB are shown in scale with the particular CG sites on the promoter.
doi:10.1371/journal.pone.0004488.g003
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normalization to b-actin as previously described [14,16]. Primers
specific for quantification of transcripts of the selected genes are
listed in Table 8. Three separate real time RT-PCRs were
performed on each FPT sample to obtain a mean value. The 2-
DDCt method was used to calculate the relative expression level of
transcripts normalized to b-actin. The mean value from a universal
reference RNA (Clontech, CA) was arbitrarily assigned an
abundance value of 1.00 for each gene. Mean values from all
other samples were normalized against this sample.
Statistical methods
The Kendall coefficient of concordance (tau) was calculated to
measure the strength of the relationship between the percent of
methylation of a gene’s promoter CGI in UCWBC DNA samples
and its transcript expression level in matched FPT RNA samples.
Ninety-five percent confidence intervals and 2-tailed p-values were
obtained to determine the expected range and significance of
observed tau values.
Chi-square tests were performed to investigate possible differences
in the percents of African Americans, males, and methylated subjects
between categories of PAH exposure, (,2.41, $2.41). Odds ratios
and 95% confidence intervals of high PAH exposure for each of the
three characteristics were calculated and tested for statistical
significance. The cutpoint of 2.41 was determined from an ROC
curve analysis following logistic regression of methylation status on
continuously measured PAH exposure. This value separated
methylated and unmethylated subjects according to ‘high/low’
PAH exposure. We considered MSPCR to be methylated above
2.41 and unmethylated below 2.41.
Figure 4. Methylation status of a region in the ACSL3 59CGI analyzed by bisufite genomic sequencing and methylation specific PCR
(MSPCR). A) Schematic diagram of the CG content (%) in the 59 flanking region of the ACSL3 gene. A CGI of 1058 bp was located at the 59 end of ACSL3
including transcription start site (TSS), untranslated region (UTR) exon1 and intron 1. Individual CG sites are marked as red vertical lines in the genomic DNA
sequence. The PCR-amplified regions were indicated by lines and methylation status of this region were determined by BSPCR and MSPCR. B) The diagram
represents the methylation status of MSPCR-amplified regions (R1–R3) of 20 samples with high or low PAH exposure with or without asthma assayed by
bisulfitegenomicsequencing.6clonesweresequencedfromeachsample.ThePAHlevelofeachsampleisshown.Opencircle:unmethylatedCG;closedcircle:
methylatedCG.MSPCR-primerswerethenspeciallydesignedonparticularregions(R1–R3).OverallMet%ofACSL3promoterisshown.Statisticaldifferencewas
acceptedatp,0.05* whencomparedwiththegroupoflowPAHwithoutasthma. C)RepresentativeresultsfromMSPCRanalyses onRegion1 (R1) ofsamples
fromthelowandhighPAHgroup.M:methylated;andU:unmethylated.ThemethylationstatusofACSL359-CGIofallsampleswasfurtheranalyzedbyMS-PCR
using the same sets of primers. Results are shown in Table 4 and Table 5. High PAH ($ the cohort median of 2.3 ng/m3), Low PAH (,the cohort median).
doi:10.1371/journal.pone.0004488.g004
Figure 5. Receiver operating characteristics (ROC) plot for 56 children on PAH values and methylation status of ACSL3 analyzed by
MSPCR. Point labels are values of PAH of each children. Statistical software, sas, was used for ROC plot and R was used for determination of cutoff
value. The cutoff value corresponds to the desired sensitivity and specificity (or 1-specificity).
doi:10.1371/journal.pone.0004488.g005
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MSPCR (N=56).
ACSL3 59CGI Methylation Status Methylated Unmethylated All Odds Ratios (95% CI’s)
Asthma (% Yes with asthma)
a 11/28 (39%) 4/28 (14%) 15/56 (27%) 3.9 (1.1, 14.3)
Median PAH exposure with in each group
b (Min, Max) 3.39 ng/m
3
(1.11, 34.48)
1.7 ng/m
3
(0.49, 3.33)
2.26 ng/m
3
(0.49, 34.48)
Note:
ap=0.03. OR=3.9 measuring the odds of asthma given ACSL3 59-CGI was methylated (M) verus unmethylated (U).
bp,0.001 testing the equality of median PAH exposure levels between subjects with methylated and unmethylated ACSL3 59CGI in their UCWBCs.
doi:10.1371/journal.pone.0004488.t005
Table 6. Population characteristics.
Category Subcategory Full cohort (N=729) Study sample (N=56) p-value
Maternal ages (yrs)(mean6SD) 25.164.9 25.464.6 0.65
Baby’s sex (%) Male 48.3 42.9 0.40
Female 51.7 57.1
Ethnicity (%) Dominican 63.5* 46.4 ,0.01
African American 36.5 53.6
Median total PAH (ng/m
3) 2.3 2.3 0.83
Probable asthmatic up to 5 years (%) 27.2 26.8 0.95
Note:
*Among N=606 samples with available data.
doi:10.1371/journal.pone.0004488.t006
Table 7. Total maternal PAH exposure levels in the study sample as compared to the full cohort.
N Min p25 p50 p75 Max Geomean 95% CI
Included in study 56 0.49 1.48 2.26 3.43 34.48 2.37 1.96, 2.86
Not included* 546* 0.27 1.45 2.29 3.69 145.00 2.38 2.23, 2.53
Note:
*There are 127 participants in the full cohort for whom we are missing prenatal PAH. No significant differences by ttest (means) or kruskal-wallis (medians). p25,
p50 and p75 denote means at the 25, 50 and 75 percentile.
doi:10.1371/journal.pone.0004488.t007
Table 4. Number (%) of African Americans, Males, and Methylated Subjects by PAH Exposure Categories (,2.41, .=2.41)
a.
Characteristics* PAH,2.41 (N=30) PAH$2.41 (N=26) Subjects (N=56) Odds Ratios (95% CI’s)
Ethnicity (%AA) 15 (50%) 15 (58%) 30 (54%) 1.4 (0.5, 3.9)
Gender (% Males) 12 (40%) 12 (46%) 24 (43%) 1.3 (0.4, 3.7)
ACSL3 59CGI Status (% Methylated) 7 (23%) 21 (81%) 28 (50%) 13.8 (3.8, 50.2)
b
Note:
*Odds Ratios, 95% Confidence Intervals (OR, 95%CI) measuring the odds of high PAH exposure in African Amercians (Compared to Dominicans), males (Compared
to Females), and subjects with methylated ACSL3 59CGI (compared to those with unmehtylated CGI) assayed by MSPCR (N=56).
aThe PAH cutpoint value 2.41 was obtained from an ROC curve where we considered that methylation status could be determined by PAH exposure level. We
considered ACSL3 59CGI to be methylated (determined by MSPCR) above 2.41 and unmethylated below 2.41. The value of the cutpoint determined the sensitivity (i.e.
number of correctly classified unmethylated subjects or true positives), the specificity (i.e. number of correctly classified unmethylated subjects or true negatives), and
the number of false positives and false negatives. The median of samples with PAH exposure ,2.41 (N=30) was 3.58 where that of samples with PAH exposure
.=2.41 was 1.55.
bp,0.001. Odds Ratio(OR)=13.8, which may also be interpreted as the odds of ACSL3 59CGI methylated when PAH=or .2.41 (compared to ,2.41).
doi:10.1371/journal.pone.0004488.t004
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between parental report of asthma (dependent variable) and
methylation status (independent variable). First, methylation status
was modeled alone; then gender and ethnicity were added to the
model. The parameter estimate and standard error of methylation
status changed less then 15% when adjusted for gender and
ethnicity, therefore the unadjusted odds ratio was presented. The
equality of the median PAH exposure levels between methylated
and unmethylated subjects was tested by the non-parametric
Kruskal-Wallis test. For all analyses a 5% alpha level indicated
significance unless stated otherwise. Analyses were performed
using SAS, Version 9.1 (SAS Institute, Cary, NC).
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Table 8. Primers for Methylation Sensitive Restriction
Fingerprinting (MSRF), Bisulfite Genomic Sequencing,
Methylation Specific PCR (MSPCR) and Real-time PCR.
Methylation Sensitive Restriction Fingerprinting
Bs7 59- GAGGTGCGCG-39
Bs10 59- AGGGGACGCG-39
Bs11 59- GAGAGGCGCG-39
Bs20 59- GCGCCGACGT-39
Bs21 59- CGGGACGCGA-39
Bs22 59- CCGCGATCGC-39
Bs23 59- TGGCCGCCGA-39
Bisulfite Genomic Sequencing
hBS_ACSL3_F1 59-GGATTTGATAGTAATTTTTGTAAGAA-39
hBS_ACSL3_R1 59-ACCTAATAACACCTACCCCACAAA-39
hBS_RAD21_F1 59-TTTAAAATAAGTATAAGAATAAAGTTAAA-39
hBS_RAD21_R1 59-AAAAAACAACAACAATCACTAACC-39
hBS_DUSP22_F1 59-GTTAAAGGGGGATTTGGAGATT-39
hBS_DUSP22_R1 59-TCACAAACACACACACAAAATCTAA-39
hBS_SCD5_F1 59-GGGATTGGAAAAATATTATAAAAGGTATT-39
hBS_SCD5_R1 59-ACAAATTCCCACTAACCACATAAAA-39
hBS_SFMBT2_F2 59-TTAAGATTGTTTTGGGGATTGAAT-39
hBS_SFMBT2_R2 59-TCCTAAACTAAAAAAAACCCCTAAC-39
hBS_WWOX_F1 59-TGTAAAATAAAGGTTGTGAATTAGTA-39
hBS_WWOX_R1 59-ACCCCTACACTCCAACCTAAATAAC-39
Methylation Specific PCR
MS_ACSL3_MF-R1 59-TTTTTGGTCGATTTCGTTTTC-39
MS_ACSL3_MR-R1 59-AAACTACCACCCATTAACCCG-39
MS_ACSL3_UF-R1 59-GTTTTTTTTGGTTGATTTTGTTTTT-39
MS_ACSL3_UR-R1 59AAACTACCACCCATTAACCCAC–39
MS_ACSL3_MF-R2 59-TCGTTTTTTTTGGTCGATTTC-39
MS_ACSL3_MR-R2 59-ATACGAAAAAACGAACGTATACGAC-39
MS_ACSL3_UF-R2 5-GTTTGTTTTTTTTGGTTGATTTTGT-39
MS_ACSL3_UR-R2 59-CAATACAAAAAAACAAACATATACAAC-39
MS_ACSL3_MF-R3 59-TTTAGGCGGTTTCGTTTAATAGAC-39
MS_ACSL3_MR-R3 59-ATACGAAAAAACGAACGTATACGAC-39
MS_ACSL3_UF-R3 59-TTAGGTGGTTTTGTTTAATAGATGT-39
MS_ACSL3_UR-R3 59-ATACAAAAAAACAAACATATACAAC-39
Real-time PCR
hACSL3_F1 59-GAGAGTTTGAACCCGATGGA-39
hACSL3_R1 59-TTGGCACAACAAATCCAATG-39
hRAD21_F1 59-AGAGCTTCCCCCAGAAGAAC-39
hRAD21_R1 59-AAGAGCACGCTGAAGACCAT-39
hDUSP22_F1 59-AGGAGCGTGACACTGGTGAT-39
hDUSP22_R1 59-CTGCCGATACTGATGGACCT-39
hSCD5_F1 59-GACCTGCTTGCTGATCCTGT-39
hSCD5_R1 59-GGGCTGATGTGCTTGTCATA-39
hSFMBT2_F1 59-GGGATTGGGTAATTTTATTTTTTTT-39
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hWWOX_F1 59-CGGATGGGAACAAGAAACTG-39
hWWOX_R1 59-CAACCACTTTGCCAGTGAAA-39
doi:10.1371/journal.pone.0004488.t008
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